Health ❯ Healthcare ❯ Patient Care

Treatment Options

Innovative Therapies Oral Medications Combination Therapy Personalized Medicine Subcutaneous Administration Chemotherapy Cognitive Impairment Targeted Therapy Endocrine Therapy Immunotherapy

FDA Grants Priority Review to Roche’s Enspryng for Thyroid Eye Disease

The decision could speed a regulatory ruling that would introduce the first at‑home, subcutaneous treatment option for moderate to severe TED.

Stories older than 24h

FDA Approves Lumvoa for Thyroid Eye Disease

Trodelvy Approved in U.S. and EU as First‑Line Option for Metastatic Triple‑Negative Breast Cancer

FDA Approves First Generic Single‑Dose Flu Drug

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

UCSF Study Identifies Cellular Loop That Weakens Brain Aneurysms

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

Finerenone Slows Kidney Decline in Non‑Diabetic CKD, Trial Shows

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

Gene Test Lets Many Over-40 Breast Cancer Patients Skip Chemotherapy

Mezigdomide Triplet Cuts Risk of Myeloma Progression by 52% in Phase 3 Trial

Germany Sees Near Doubling of Hospital Skin‑Cancer Treatments Over 20 Years

FDA Approves Decnupaz for Rare Blood Cancer

FDA Extends Review of AstraZeneca’s Camizestrant

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

FDA Approves Datroway as First‑Line Option for Immunotherapy‑Ineligible Triple‑Negative Breast Cancer